ESTELLAREGN7544 Antibody for Sepsis-Induced Hypotension

This clinical trial is exploring a new experimental drug called REGN7544 for treating patients with sepsis-induced hypotension. Sepsis is a serious condition caused by an overwhelming infection, leading to dangerously low blood pressure. The study focuses on adults aged 18 to 85 who are hospitalized due to sepsis and are already receiving standard treatments to raise their blood pressure. The main goal is to determine if REGN7544 can safely and effectively help manage low blood pressure in these patients, which is a crucial aspect of their care. Participants in the study will receive REGN7544 in addition to their regular care and will be closely monitored to see how the drug affects their blood pressure and the amount of medication they need to stabilize it. Researchers will also track any side effects, how the drug behaves in the body over time, and whether the body develops antibodies against it, potentially impacting its effectiveness. The study involves regular blood tests and health evaluations to gather this information, ensuring a comprehensive understanding of the drug's impact on sepsis-related low blood pressure.